Drugmaker recalls samples of antiplatelet drugAstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.
FDA expands Brilinta approval for long-term use in patients with heart attack historyFDA has expanded approval for ticagrelor (Brilinta, AstraZeneca) to include long-term use in patients with a history of heart attack.
Prescribing, dispensing errors seen with Brintellix, BrilintaFDA issued a drug safety warning that there have been 50 reports of medication errors because of confusion between the antidepressant Brintellix (vortioxetine) and the antiplatelet agent Brilinta (ticagrelor).
FDA grants priority review to expand use of BrilintaThe FDA has granted Priority Review for ticagrelor (Brilinta, AstraZeneca) for patients with a history of heart attack.
FDA drug approvals-April 2015FDA actions in brief, priority review, breakthrough therapy designation, fast-track designations, orphan drug designations, first-time generic approvals
FDA drug approvals-March 2015FDA actions in brief, breakthrough designation, recommended for approval, priority review, fast-track designations